Sacubitril And Valsartan Tablet
Product Images NDC 71610-984

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 71610-984). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0984 37)

This text provides information on a batch of 3120 tablets containing Valsartan and Sacubitril/Valsartan in specific quantities. It lists the NDC number, storage instructions, manufacturer details, repackager information, and other relevant details such as GTIN and batch numbers. It highlights the importance of storing the medication at room temperature and out of children's reach.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

545 (Sacubitril Valsartan Fig 1)

This text provides a comparison of different drugs with a reference on the basis of the geometric mean ratio and 90% confidence interval. The drugs mentioned for comparison include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ (Hydrochlorothiazide), Metformin, Alorvastatin, and Sildenafil. The values indicate how each drug's efficacy or potency changes concerning the reference drug.*

FDA Label Image

665 (Sacubitril Valsartan Fig 2)

FDA Label Image

898 (Sacubitril Valsartan Fig 3a)

This text provides information on the time to the first occurrence of cardiovascular (CV) death or heart failure hospitalizations in the PARADIGM-HF study. It includes statistical data showing a significant difference between the treatment groups represented by enalapril and sacubitril/valsartan. The hazard ratio (HR) with a 95% confidence interval is given as 0.80 (0.73, 0.87), indicating a lower risk in the sacubitril and valsartan group. The failure rate over time is also presented graphically. This data is valuable for understanding the outcomes and efficacy of these medications in heart failure treatment.*

FDA Label Image

212 (Sacubitril Valsartan Fig 3b)

This text provides information about the time to occurrence of cardiovascular (CV) death in the PARADIGM-HF study. It includes hazard ratios (HR) with confidence intervals for Sacubitril and Valsartan compared to Enalapril. The data also shows the failure rates percentage over time for both treatments, along with the number at risk and time since randomization in days for each treatment group.*

FDA Label Image

554 (Sacubitril Valsartan Fig 3c)

This document appears to provide data on the Time to First Occurrence of Heart Failure Hospitalizations in the PARADIGM-HF study. It includes information on failure rate percentages, the number at risk for Sacubitril & Valsartan and Enalapril, and hazard ratios. Additionally, it presents a timeline since randomization in days and the number of individuals at risk at various time points.*

FDA Label Image

565 (Sacubitril Valsartan Fig 4)

FDA Label Image

989 (Sacubitril Valsartan Fig 5)

This text provides data on the time to heart failure hospitalization and cardiovascular death in the PARAGON-HF study. The chart shows the number of subjects at risk over time for the two treatments: Sacubitril Valsartan and Valsartan, with the corresponding count decreasing over days.*

FDA Label Image

565 (Sacubitril Valsartan Fig 6)

FDA Label Image

656 (Sacubitril Valsartan Fig 7)

This text provides a comparison of treatments in heart failure trials, specifically looking at the use of sacubitrl and valsartan versus valsartan in PARAGON-HF and sacubitrl and valsartan versus enalapril in PARADIGM-HF. It also mentions left ventricular ejection fraction at screening. This information may be useful for understanding the efficacy of these medications in heart failure patients.*

FDA Label Image

565 (Sacubitril Valsartan Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.